论文部分内容阅读
1979年起,第二军医大学附属长征医院儿科和上海信谊药厂协作,研制成功手控式人白细胞干扰索气雾剂(IFN-α气雾剂),气雾剂内干扰素的生物效价,无明显降低。80％以上的气雾剂颗粒直径<5μm。动物试验未见刺激反应。临床应用IFN-α气雾剂,对小儿流行性感冒、RSV引起毛细支气管炎、流腮、感染型哮喘和哮喘性支气管炎及反复上呼吸道感染,均有良好疗效,且有无创伤性、无副作用和安全可靠以及药源经济和使用方便等优点。
Since 1979, the Changsheng Hospital affiliated to the Second Military Medical University and the Shanghai Xinyi Pharmaceutical Factory have collaborated on the successful development of a manual-controlled human leukocyte-interfering aerosol (IFN-α aerosol) aerosol interferon bioavailability Price, no significant reduction. More than 80% of the aerosol particles have a diameter of <5 μm. Animal tests showed no irritation. Clinical application of IFN-α aerosol has good curative effect on pediatric influenza, RSV-induced bronchiolitis, gondola, infectious asthma and asthmatic bronchitis and recurrent upper respiratory tract infection, with or without trauma Side effects and safety and reliability as well as medicine source economy and ease of use and so on.